Claims
- 1. A diarylmethylidenefuran compound of formula (I): wherein:the rings A and B independently are: a phenyl radical: a napthyl radical; a pyridyl radical; at least one of said rings A and B necessarily representing a phenyl radical; at least one of the substituents X1, X2, Y1 or Y2 is necessarily: an S(O)n—R group, in which n is an integer equal to 0, 1 or 2 and R is a lower alkyl radical having 1 to 6 carbon atoms or a lower haloalkyl radical having 1 to 6 carbon atoms, or an SO2NH2 group; and is located in the para position on said phenyl radical when A or B represents a phenyl radical,the others independently being: a hydrogen atom, a halogen atom, a lower alkyl radical having 1 to 6 carbon atoms, a trifluoromethyl radical, a lower O-alkyl radical having 1 to 6 carbon atoms, or X1 and X2 or Y1 and Y2 are a methylenedioxy group; and R1, R2, R3 and R4 independently are: a hydrogen atom, a halogen atom, a lower alkyl radical having 1 to 6 carbon atoms, a lower haloalkyl radical having 1 to 6 carbon atoms, an aromatic radical selected from the group consisting of phenyl and naphthyl; or R1R2 or R3R4 are an oxygen atom, or R1,R2 or R3,R4, together with the carbon atom to which they are attached, form a saturated hydrocarbon ring having from 3 to 7 carbon atoms.
- 2. A compound of formula (I) according to claim 1, wherein:the rings A and B independently are: a phenyl radical, a naphthyl radical, a pyridyl radical; at least one of the substituents X1, X2, Y1 or Y2 is necessarily and SCH3, SO2CH3 or SO2NH2 group, the others independently being: a hydrogen atom, a halogen atom, a lower alkyl radical having 1 to 6 carbon atoms, a trifluoromethyl radical, or a lower O-alkyl radical having 1 to 6 carbon atoms; R1R2 are an oxygen atom; and R3R4 independently are a hydrogen atom or a lower alkyl radical having 1 to 6 carbons.
- 3. A compound according to claim 1, wherein the ring B is a phenyl radical.
- 4. A compound according to claim 1, wherein the ring A is a phenyl radical or a pyridyl radical.
- 5. A compound according to claim 1, wherein X1 is a 4-SO2CH3 group or a 4-SO2NH2 group, and X2 is a hydrogen atom.
- 6. A compound according to claim 1, wherein Y1 is a fluorine atom, a chlorine atom, a bromine atom or a methyl radical, and Y2 is a hydrogen atom, a fluorine atom, a chlorine atom, or a bromine atom.
- 7. A compound according to claim 1, wherein R1R2 are an oxygen atom and R3 and R4 are each a hydrogen atom.
- 8. A compound according to claim 1, and having the formula
- 9. A compound according to claim 1 which is (E)-4-[(4-methylphenyl)(tetrahydro-2-oxo-3-furanylidene)methyl]benzenesulfonamide or (Z)-3-[1-(4-bromophenyl)-1-(4-methylsulfonylphenyl)methylidene]dihydrofuran-2-one.
- 10. A compound according to claim 1 which is (Z)-3-[1-(4-bromophenyl)-1-(4-methylsulfonylphenyl)methylidene]dihydrofuran-2-one.
- 11. A pharmaceutical composition, which comprises a pharmaceutically effective amount of a compound of formula (I) as defined in claim 1, incorporated in a pharmaceutically acceptable excipient, vehicle or carrier.
- 12. A pharmaceutical composition with anti-inflammatory and analgesic activity, which contains a pharmaceutically effective amount of a compound of formula (I) as defined claim 1, incorporated in a pharmaceutically acceptable excipient, vehicle or carrier.
- 13. A pharmceutical composition as defined in claim 1, useful in the prevention of cancer, in particular adenocarcinoma of the colon, in the prevention of neurodegenerative diseases, especially Alzheimer's disease, in the prevention of stroke and epilepsy, and in the prevention of premature labour.
- 14. A pharmaceutical composition according to claim 11, which is in the form of gelatin capsules or tablets containing a dose of 1 mg to 1000 mg.
- 15. A pharmaceutical composition according to claim 11, which is in the form of of injectable preparations containing a dose of 0.1 mg to 500 mg.
- 16. A method for treating inflammation in a mammal which comprises adminstering an anti-inflammatory effective amount of a compound of formula I as defined in claim 1 to said mammal.
- 17. A method for treating pain in a mammal which comprises administering an effective amount of a compound of formula I as defined in claim 1 to said mammal.
Priority Claims (2)
Number |
Date |
Country |
Kind |
96 04326 |
Apr 1996 |
FR |
|
96 07922 |
Jun 1996 |
FR |
|
Parent Case Info
This is a continuation-in-part of U.S. application Ser. No. 09/125,846, filed Aug. 26, 1998, now abandoned which is a continuation-in-part of U.S. application Ser. No. 08/825,242, filed Mar. 27, 1997, now U.S. Pat. No. 5,807,873 which is a continuation-in-part of U.S. application Ser. No. 08/714,742, filed Sep. 16, 1996, now abandoned, claiming priorities from French Patent Application No. 9604236, filed on Apr. 4, 1996 and from French Patent Application No. 9607922, filed on Jun. 26, 1996.
US Referenced Citations (7)
Foreign Referenced Citations (5)
Number |
Date |
Country |
WO9415932 |
Jul 1994 |
WO |
WO9500501 |
Jan 1995 |
WO |
WO9608482 |
Mar 1996 |
WO |
WO9636623 |
Nov 1996 |
WO |
WO9843966 |
Oct 1998 |
WO |
Non-Patent Literature Citations (3)
Entry |
Gilbert, et al., J. Med. Chem., 1983, 26: 693-699. |
Katsumi, et al., Chem. Pharm. Bull., 1986, 34(1): 121-129. |
Katsumi, et al., Chem. Pharm. Bull., 1986, 34(4): 1619-1627. |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09/125846 |
Aug 1998 |
US |
Child |
09/150388 |
|
US |
Parent |
08/825242 |
Mar 1997 |
US |
Child |
09/125846 |
|
US |
Parent |
08/714742 |
Sep 1996 |
US |
Child |
08/825242 |
|
US |